Pirfenidone

compare suppliers & send inquiries for free

Looking for Pirfenidone 53179-13-8?

Description:

Here you will find a list of producers, manufacturers and traders of Pirfenidone. You can sort by certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.

API | Excipient name:

Pirfenidone 

Synonyms:

 

Cas Number:

53179-13-8 

DrugBank number:

DB04951 

Unique Ingredient Identifier:

D7NLD2JX7U

Pirfenidone is a type of Antifibrotic agents

Antifibrotic agents belong to the pharmaceutical API category that focuses on treating fibrosis, a condition characterized by the excessive accumulation of fibrous connective tissue in organs. These agents target the underlying mechanisms involved in fibrosis and help prevent or slow down the progression of the disease.

One commonly used antifibrotic agent is Pirfenidone, which has shown efficacy in treating idiopathic pulmonary fibrosis (IPF). It works by inhibiting the production of pro-inflammatory and fibrotic factors, such as transforming growth factor-beta (TGF-β), platelet-derived growth factor (PDGF), and fibroblast growth factor (FGF). By reducing the levels of these factors, Pirfenidone helps suppress the proliferation and activation of fibroblasts, which are responsible for excessive collagen deposition in fibrotic tissues.

Another antifibrotic agent, Nintedanib, also targets IPF. It is a tyrosine kinase inhibitor that blocks the activity of various growth factor receptors, including PDGF, fibroblast growth factor receptor (FGFR), and vascular endothelial growth factor receptor (VEGFR). By inhibiting these receptors, Nintedanib disrupts the signaling pathways involved in fibrosis, thereby reducing fibroblast activation and collagen production.

These antifibrotic agents have shown promising results in clinical trials and have been approved for the treatment of IPF in several countries. They represent a significant advancement in the management of fibrotic diseases and offer hope to patients by slowing down disease progression and improving overall outcomes.

In conclusion, antifibrotic agents are a vital category of pharmaceutical APIs that target the underlying mechanisms of fibrosis. Through their action on key molecular pathways involved in fibrotic tissue deposition, these agents help reduce the accumulation of fibrous connective tissue and provide potential therapeutic benefits for patients with fibrotic diseases.

• Shilpa Medicare Ltd from India
• TIEFENBACHER API + Ingredients from Germany
• Lupin from India
• Rolabo Outsourcing from Spain
• Raks Pharma from India
• Fabbrica Italiana Sintetici (FIS) from Italy
• Honour Lab from India
• Signa from Mexico
• Laurus Labs from India
• Chemeca Drugs pvt Ltd from India
• Jubilant Generics from India
• Beijing Hope from China
• Alven Laboratories from Czech Republic
• Chemo Iberica from Spain
• MSN Pharma from India
• MSN Life Sciences from India
• ZCL Chemicals from India
• Aurobindo from India
• Dipharma Francis S.r.l. from Italy
• Optimus Drugs Pvt Ltd from India
• Micro Labs from India
• Granules India from India
• Pharmazell from Germany
• Glenmark Pharma from India
• Mylan from India
• Procos from Italy
• Alembic Pharma from India
• Cipla from India

Let the supplier know whether you are looking for a product with a specific monograph such as EP (Ph. Eur.), USP, JP, BP or another quality. Or, whether you are looking for hydrochloride (HCl), anhydricum, base, micronisatum or a specific purity.

You can use the filters to find high-quality suppliers. For example, you can select GMP, FDA or ISO certified suppliers. Visit our FAQ page or use the chat box in the corner to get more information about Pharmaoffer.